Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Receivables - Other came in at $9.0 million in Q1 2026, up 23.97% year-on-year from $7.2 million in Q1 2025, and up 15.46% quarter-over-quarter from $7.8 million in Q4 2025.
Crinetics Pharmaceuticals has reported Receivables - Other for 10 years, with the latest figure at $9.0 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other rose 23.97% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (up 23.97% YoY), and the FY2025 full-year result was $7.8 million, down 6.64% from the prior year.
- Receivables - Other for Q1 2026 stood at $9.0 million, up from $7.8 million in the prior quarter.
- The five-year high for Receivables - Other was $9.0 million in Q1 2026, with the low at $92000.0 in Q3 2022.
- Average Receivables - Other over 5 years is $3.8 million, with a median of $3.1 million recorded in 2023.
- Year-over-year, Receivables - Other slumped 96.49% in 2024 and surged 6791.3% in 2025.
- Tracing CRNX's Receivables - Other over 5 years: stood at $1.4 million in 2022, then jumped by 125.5% to $3.1 million in 2023, then surged by 172.37% to $8.3 million in 2024, then decreased by 6.64% to $7.8 million in 2025, then climbed by 15.46% to $9.0 million in 2026.
- The last three Receivables - Other figures came in at $9.0 million (Q1 2026), $7.8 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.96 Mn |
| Mar 31, 2026 | 8.96 Mn |
| Dec 31, 2025 | 7.76 Mn |
| Dec 31, 2025 | 7.76 Mn |
| Sep 30, 2025 | 6.34 Mn |
| Sep 30, 2025 | 6.34 Mn |
| Jun 30, 2025 | 8.38 Mn |
| Jun 30, 2025 | 8.38 Mn |
| Mar 31, 2025 | 7.23 Mn |
| Mar 31, 2025 | 7.23 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.48 Mn |
| Mar 31, 2024 | 3.17 Mn |
| Mar 31, 2024 | 3.17 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 897,000.00 |
| Jun 30, 2023 | 897,000.00 |
| Mar 31, 2023 | 1.27 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 92,000.00 |
| Sep 30, 2022 | 92,000.00 |
| Jun 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 619,000.00 |
| Mar 31, 2022 | 619,000.00 |
| Dec 31, 2021 | 553,000.00 |
| Dec 31, 2021 | 553,000.00 |
| Sep 30, 2021 | 86,000.00 |
| Sep 30, 2021 | 86,000.00 |
| Jun 30, 2021 | 113,000.00 |
| Jun 30, 2021 | 113,000.00 |
| Mar 31, 2021 | 85,000.00 |
| Mar 31, 2021 | 85,000.00 |
| Dec 31, 2020 | 113,000.00 |
| Dec 31, 2020 | 113,000.00 |
| Sep 30, 2020 | 125,000.00 |
| Sep 30, 2020 | 125,000.00 |
| Jun 30, 2020 | 116,000.00 |
| Jun 30, 2020 | 116,000.00 |
| Mar 31, 2020 | 139,000.00 |
| Mar 31, 2020 | 139,000.00 |
| Dec 31, 2019 | 224,000.00 |
| Dec 31, 2019 | 224,000.00 |
| Sep 30, 2019 | 269,000.00 |
| Sep 30, 2019 | 269,000.00 |
| Jun 30, 2019 | 300,000.00 |
| Jun 30, 2019 | 300,000.00 |
| Mar 31, 2019 | 415,000.00 |
| Mar 31, 2019 | 415,000.00 |
| Dec 31, 2018 | 340,000.00 |
| Dec 31, 2018 | 340,000.00 |
| Sep 30, 2018 | 510,000.00 |
| Sep 30, 2018 | 510,000.00 |
| Jun 30, 2018 | 657,000.00 |
| Jun 30, 2018 | 657,000.00 |
| Dec 31, 2017 | 231,000.00 |
| Dec 31, 2017 | 231,000.00 |